We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Publishes First RMP Summary, Paving Way for More Transparency
EMA Publishes First RMP Summary, Paving Way for More Transparency
The European Medicines Agency March 11 published the first risk-management plan summary for Piramal Imaging’s molecular imaging agent NeuraCeq (florbetaben (18F)), used to detect ? amyloid plaques in the brain, a protein associated with Alzheimer’s disease.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor